Surasak Nilganuwong

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Efficacy and Safety of Single and Double Doses of Ivermectin versus 7-Day High Dose Albendazole for Chronic Strongyloidiasis

Yupin Suputtamongkol, Nalinee Premasathian, Kid Bhumimuang et al. · PLoS neglected tropical diseases · 2011 · 166 citations · Full text

Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Intravenous, Dose‐Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus

Jacek C. Szepietowski, Surasak Nilganuwong, Anna Woźniacka et al. · Arthritis & Rheumatism · 2013 · 111 citations

The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study

Worawit Louthrenoo, Surasak Nilganuwong, Sek Aksaranugraha et al. · Osteoarthritis and Cartilage · 2007 · 65 citations · Full text

Anti-inflammatory, Painful Knee Osteoarthritis, Pain Medicine +8

Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4‐week, multinational, randomized, double-blind study

Cristiano A. F. Zerbini, Zafer E. Ozturk, Joachim Grifka et al. · Current Medical Research and Opinion · 2005 · 62 citations